In the month of March 2020, I researched on the infamous Stanford Bio Design Group.
Stanford-India Biodesign was launched in 2007 as a first-of-its-kind collaboration between Stanford University, the All India Institute of Medical Sciences (AIIMS), and the Indian Institute of Technology (IIT) Delhi. The goal of the partnership was to identify and train a first generation of local innovation leaders in medical technology who, in turn, would help stimulate India’s nascent medtech industry.
Each year, four India fellows came to Stanford to spend six months working in multidisciplinary teams to learn and apply biodesign process to real-world healthcare projects identified in Stanford’s hospitals and clinics. The fellows would then return to Delhi to repeat the process, this time to address the unmet healthcare needs of Indian patients, physicians, and healthcare facilities, and to take their innovative solutions forward into patient care.
Over the program’s nine-year duration, Stanford-India Biodesign trained 32 innovators who developed 14 technologies and started 13 companies. With this successful track record, our Indian partners transitioned to independent status and the program is now known as the School of International Biodesign, based at AIIMS.